Amoxapine in the treatment of depression. A clinical evaluation in ambulant patients.
Amoxapine (Demolox; Lederle), an antidepressive agent, was administered to 24 patients suffering from pathological depression in an open uncontrolled single-blind study. The dosage ranged from 75 to 150 mg/d. Four patients dropped out of the study owing to side-effects and 1 because of rapid improvement. The 19 showed a marked improvement and experienced no side-effects. There were firm indications that improvement can be expected within 7 days.
D000328:Adult; D000657:Amoxapine / Q000009:adverse effects / Q000627:therapeutic use*; D002986:Clinical Trials as Topic; D003863:Depression / Q000188:drug therapy*; D003989:Dibenzoxazepines / Q000627:therapeutic use*; D004341:Drug Evaluation; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D011569:Psychiatric Status Rating Scales; D013997:Time Factors
D003989:Dibenzoxazepines; D000657:Amoxapine